1
1
1
1
2
2
2
2
1
1
1
1
1
1
2018
1992
Company (9)University (3)
1 - 9 of 9
Sort by
Patent
Publication NumberUS 8945566Filing StatusIssued PatentAvailabilityUnknownFiling Date2012-04-26Publication Date2015-02-03
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE …
Patent
Publication NumberUS 8697079Filing StatusIssued PatentAvailabilityUnknownFiling Date2012-02-14Publication Date2014-04-15
The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antige…
Patent
Publication NumberUS 20110256124Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2010-10-07Publication Date2011-10-20
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE …
Patent
Publication NumberUS 20110091466Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2010-10-07Publication Date2011-04-21
The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antige…
Research Grant
Project Number1R41CA137881-01Funding AgencyNational Institutes of HealthEffective Date2009-05-01Expiration Date2010-07-31Funding Amount$158,851
DESCRIPTION (provided by applicant): The present proposal seeks to develop a novel anti-prostate specific antigen (PSA) IgE antibody for the treatment of prostate cancer (PCA) with the goal to induce a hypersensitivity reaction to the tumor. The objective of this proposal is to generate the anti-PSA IgE and to demonstrate that this anti-PSA IgE will target the tumor by two parallel pathways: a) by mediating bystander antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP)…
Research Grant
Project Number7F32DK078416-03Funding AgencyNational Institutes of HealthEffective Date2009-03-15Expiration Date2010-03-14Funding Amount$53,354
DESCRIPTION (provided by applicant): Nephritis is a common complication of the human autoimmune disease systemic lupus erythematosus (SLE). Mice of the MRL-Faslpr strain spontaneously develop a disease that is similar to SLE. It has been shown that macrophages (MO) are prominent in lupus nephritis in the MRL-Faslpr strain and that upon activation, MO destroy renal resident cells during inflammation. Colony Stimulating Factor-1 (CSF-1), the principal MO growth factor, is required to promote lu…
Patent
Publication NumberUS 5447939Filing StatusIssued PatentAvailabilityUnknownFiling Date1994-07-25Publication Date1995-09-05
Disclosed herein are methods directed generally to the control of neural activity and to the treatment of neural disorders. More particularly, the present invention is directed to methods for the modification of mammalian neural activity through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of neurological activities and to therapeutically or prophylactically treat a wide var…
Patent
Publication NumberUS 5091432Filing StatusIssued PatentAvailabilityUnknownFiling Date1990-03-28Publication Date1992-02-25
Novel bi-functional pharmaceutical compounds, particularly novel 9-substituted hypoxanthines of the general formula: ##STR1## where R is a neurologically active moiety, are described as pharmaceutical agents for treating neuroimmunologic disorders in mammals. Novel methods for the utilization of these compounds are also disclosed. These compounds exhibit uniquely dose-dependent, synergistic biological properties and are particularly useful for treating interrelated physiological systems.
We found 9 documents that match your Search
Research Grants: 2
Patents: 7

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in